RecruitingPhase 3NCT07395232
An Efficacy and Safety Study of DFL24498 in the Treatment of AKC
Studying Atopic keratoconjunctivitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dompé Farmaceutici S.p.A
- Intervention
- DFL24498(drug)
- Enrollment
- 138 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2025 – 2027
Study locations (19)
- Bowden Eye Associates - Southside Location, Jacksonville, Florida, United States
- University of Miami, Miller School of Medicine, Bascom Palmer Eye Institute, Miami, Florida, United States
- Clayton Eye Clinical Research, Morrow, Georgia, United States
- Ophthalmology Associates, St Louis, Missouri, United States
- NYU Langone Health - Eye Center, New York, New York, United States
- Duke Eye Center - Ophthalmology, Durham, North Carolina, United States
- Total Eye Care, PA, Memphis, Tennessee, United States
- Baylor University Jamail Specialty Care Center- Alkek Eye Center- Ophthalmology, Houston, Texas, United States
- IRCCS AOU di Bologna - Policlinico Sant'Orsola UO Oftalmologia, Bologna, Italy
- Ospedale SS Annunziata, ASL 2 Lanciano Vasto Chieti, Chieti, Italy
- Azienda Ospedaliero Universitaria Careggi, Florence, Italy
- Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy
- AOU Policlinico Umberto I, Roma, Italy
- Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
- METAVISION ARRUZAFA S.L. (Hospital Arruzafa), Córdoba, Spain
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07395232 on ClinicalTrials.govOther trials for Atopic keratoconjunctivitis
Additional recruiting or active studies for the same condition.